ReviewCurrent medical science2026
Chromosome Karyotyping in Hematological Malignancies: Current Status and Future Directions.
Review in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chromosome karyotyping, particularly G-banding, is a fundamental diagnostic and prognostic tool for hematological malignancies, providing a genome-wide view of large-scale numerical and structural chromosomal abnormalities. Its clinical utility is paramount for disease classification, risk stratification, and the evaluation of hematopoietic stem cell transplantation (HSCT) across diseases such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndromes (MDS). However, clinical challenges including low resolution and culture failure necessitate complementary advanced techniques. Fluorescence in situ hybridization (FISH) targets specific aberrations in non-dividing cells, while array comparative genomic hybridization (aCGH) and single-nucleotide polymorphism (SNP) arrays offer higher resolution for detecting cryptic copy number variations (CNVs) and copy-neutral loss of heterozygosity (CN-LOH). Furthermore, the modern diagnostic standard has evolved into a multi-omics approach that integrates morphology, flow cytometry, karyotyping, and next-generation sequencing (NGS). This comprehensive workflow significantly enhances diagnostic accuracy, refines risk stratification, and informs personalized therapeutic strategies. Clinically, karyotyping is essential for assessing cytogenetic remission, though it is less sensitive for minimal residual disease (MRD) detection than molecular methods. As emerging technologies such as optical genome mapping (OGM) demonstrate the potential to streamline these workflows, karyotyping continues to evolve, solidifying its indispensable role in the comprehensive management of hematologic cancers.
Indexed as
Identifiers
41926042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.